MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.

Szczegóły
Abstrakt

Tytuł:: MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.
Autorzy:: Seo HA; Department of Biomedical Science and Research Institute for Bioscience & Biotechnology, Hallym University, Chunchon 24252, Korea.
Moeng S; Department of Biomedical Science and Research Institute for Bioscience & Biotechnology, Hallym University, Chunchon 24252, Korea.
Sim S; Generoath, Seachang-ro, Mapo-gu, Seoul 04168, Korea.
Kuh HJ; Department of Medical Life Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
Choi SY; Department of Biomedical Science and Research Institute for Bioscience & Biotechnology, Hallym University, Chunchon 24252, Korea.
Park JK; Department of Biomedical Science and Research Institute for Bioscience & Biotechnology, Hallym University, Chunchon 24252, Korea.
Źródło:: Cells [Cells] 2019 Dec 20; Vol. 9 (1). Date of Electronic Publication: 2019 Dec 20.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Original Publication: Basel, Switzerland : MDPI
MeSH Terms:: Antineoplastic Agents/*therapeutic use
MicroRNAs/*genetics
Neoplasms/*drug therapy
Antineoplastic Agents/pharmacology ; Drug Resistance, Neoplasm/drug effects ; Drug Synergism ; Extracellular Vesicles/drug effects ; Extracellular Vesicles/genetics ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; MicroRNAs/antagonists & inhibitors ; Neoplasms/genetics
References:: J Biol Chem. 2014 Sep 19;289(38):26038-56. (PMID: 25077968)
Cells. 2016 Mar 29;5(2):. (PMID: 27043634)
Mol Cell. 2011 Jan 21;41(2):210-20. (PMID: 21195000)
Nat Med. 2011 Dec 11;18(1):74-82. (PMID: 22157681)
PLoS One. 2013 Oct 02;8(10):e76402. (PMID: 24098490)
BMC Genomics. 2013;14 Suppl 5:S17. (PMID: 24552551)
Mol Genet Genomics. 2018 Oct;293(5):1159-1167. (PMID: 29752546)
Exp Cell Res. 2018 Jan 15;362(2):386-393. (PMID: 29223442)
Autophagy. 2015;11(2):373-84. (PMID: 25650716)
Cancers (Basel). 2019 Feb 18;11(2):. (PMID: 30781685)
Cancers (Basel). 2017 Aug 23;9(9):. (PMID: 28832494)
Oncogene. 2019 Jun;38(25):5076-5090. (PMID: 30905967)
Cell. 2019 Jan 10;176(1-2):11-42. (PMID: 30633901)
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162. (PMID: 30423142)
Oncol Rep. 2013 Mar;29(3):1037-42. (PMID: 23291714)
Sci Rep. 2017 Mar 24;7(1):416. (PMID: 28341864)
DNA Cell Biol. 2016 May;35(5):249-56. (PMID: 26845645)
Cancer Cell. 2016 Jul 11;30(1):147-160. (PMID: 27411589)
Stem Cells. 2012 Sep;30(9):1808-18. (PMID: 22730244)
Cancer Lett. 2019 Sep 10;459:122-134. (PMID: 31173853)
Sci Rep. 2017 Jan 11;7:40384. (PMID: 28074905)
Sci Rep. 2016 Oct 27;6:36134. (PMID: 27786305)
Mol Cancer. 2017 Jul 25;16(1):132. (PMID: 28743280)
J Drug Target. 2015;23(6):519-24. (PMID: 25714665)
Nature. 2017 Oct 19;550(7676):360-365. (PMID: 28976962)
Cancer Lett. 2017 Mar 1;388:107-117. (PMID: 27940128)
Exp Mol Pathol. 2019 Feb;106:34-43. (PMID: 30539797)
Cell Death Dis. 2015 May 21;6:e1766. (PMID: 25996293)
Mol Ther. 2019 May 8;27(5):1039-1050. (PMID: 30852137)
Gene. 2019 Jun 5;700:110-119. (PMID: 30917930)
Genes Dev. 2013 May 1;27(9):1059-71. (PMID: 23651858)
J Cell Mol Med. 2018 Jul;22(7):3526-3536. (PMID: 29664235)
Cancer Res. 2011 Dec 15;71(24):7608-16. (PMID: 22009537)
EBioMedicine. 2018 Sep;35:204-221. (PMID: 30146342)
J Cell Physiol. 2020 Jan;235(1):185-193. (PMID: 31190335)
Int J Oncol. 2018 Dec;53(6):2769-2779. (PMID: 30320370)
Mol Cancer Ther. 2007 Jul;6(7):2092-102. (PMID: 17620438)
Cell Death Dis. 2017 May 11;8(5):e2770. (PMID: 28492560)
J Exp Clin Cancer Res. 2019 Feb 4;38(1):51. (PMID: 30717752)
Int J Biol Macromol. 2018 Oct 1;117:445-453. (PMID: 29852230)
Mol Cell Ther. 2014 May 27;2:15. (PMID: 26056583)
Cancer Sci. 2013 Oct;104(10):1303-8. (PMID: 23822562)
Oncogene. 2010 Sep 23;29(38):5299-310. (PMID: 20622903)
Mol Cancer Res. 2016 Oct;14(10):928-940. (PMID: 27358111)
Cells. 2018 Aug 01;7(8):. (PMID: 30071693)
Nat Commun. 2014 Oct 28;5:5241. (PMID: 25348003)
Hepatology. 2018 Apr;67(4):1392-1407. (PMID: 29108133)
J Exp Clin Cancer Res. 2018 Mar 12;37(1):52. (PMID: 29530052)
Cancers (Basel). 2015 Aug 11;7(3):1554-85. (PMID: 26270676)
Cell Death Differ. 2018 Feb;25(2):406-420. (PMID: 29125598)
Clin Cancer Res. 2014 Mar 1;20(5):1146-57. (PMID: 24327274)
Oncotarget. 2017 Nov 18;8(64):107500-107512. (PMID: 29296182)
Int J Mol Sci. 2018 Apr 16;19(4):. (PMID: 29659498)
Basic Clin Pharmacol Toxicol. 2018 Jul;123(1):8-13. (PMID: 29345051)
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40. (PMID: 19193853)
Cell Rep. 2019 Mar 5;26(10):2667-2680.e7. (PMID: 30840889)
Nat Commun. 2016 Mar 29;7:11150. (PMID: 27021436)
Oncotarget. 2017 Dec 12;8(70):114856-114876. (PMID: 29383126)
Cells. 2016 May 13;5(2):. (PMID: 27187479)
Cancer Res. 2012 Jul 1;72(13):3238-50. (PMID: 22719072)
Cell Rep. 2018 Apr 3;23(1):100-111. (PMID: 29617652)
Mol Carcinog. 2017 Jun;56(6):1543-1553. (PMID: 28112439)
Oncogene. 2018 Aug;37(31):4300-4312. (PMID: 29717264)
Cancer Gene Ther. 2018 May;25(3-4):68-76. (PMID: 29302045)
Int J Biochem Cell Biol. 2019 Jun;111:63-71. (PMID: 30710750)
Mol Cell Biol. 2017 Mar 1;37(6):. (PMID: 27994014)
Cancer Lett. 2017 Dec 1;410:212-227. (PMID: 28965855)
Oncogene. 2014 Jun 19;33(25):3267-76. (PMID: 23893241)
Autophagy. 2013 Mar;9(3):424-5. (PMID: 23321721)
Int J Cancer. 2018 Jan 1;142(1):109-120. (PMID: 28905994)
BMC Bioinformatics. 2017 Sep 2;18(1):388. (PMID: 28865443)
Hepatology. 2014 Mar;59(3):1030-42. (PMID: 24122873)
Oncogenesis. 2018 Feb 20;7(2):16. (PMID: 29459645)
Cell. 2019 Jun 13;177(7):1682-1699. (PMID: 31199916)
PLoS One. 2011;6(11):e26753. (PMID: 22110593)
Cancer Res. 2014 Dec 15;74(24):7573-82. (PMID: 25368020)
Int J Mol Sci. 2018 Sep 11;19(9):. (PMID: 30208623)
Cancer Lett. 2017 Jun 1;395:53-62. (PMID: 28274892)
J Cell Mol Med. 2017 Sep;21(9):1929-1943. (PMID: 28411377)
Mol Ther. 2018 Mar 7;26(3):744-754. (PMID: 29475734)
Nat Cell Biol. 2014 May;16(5):457-68. (PMID: 24747441)
Mol Cancer Ther. 2005 Dec;4(12):1936-42. (PMID: 16373708)
Biochem Pharmacol. 2018 Feb;148:13-26. (PMID: 29208365)
Cancer Biol Ther. 2019;20(7):989-998. (PMID: 30983514)
J Cell Biol. 2013 Feb 18;200(4):373-83. (PMID: 23420871)
Cell Signal. 2013 Dec;25(12):2693-701. (PMID: 24018051)
Mol Cancer Ther. 2006 Jul;5(7):1800-6. (PMID: 16891466)
Int J Mol Sci. 2013 May 23;14(6):10749-60. (PMID: 23702845)
EBioMedicine. 2019 Mar;41:395-407. (PMID: 30803931)
Oncol Rep. 2013 May;29(5):2019-24. (PMID: 23483142)
J Exp Clin Cancer Res. 2017 Apr 13;36(1):53. (PMID: 28407783)
PLoS One. 2015 May 11;10(5):e0126499. (PMID: 25962180)
Radiother Oncol. 2008 Mar;86(3):383-90. (PMID: 18037521)
Mol Carcinog. 2018 Sep;57(9):1223-1236. (PMID: 29749061)
Nat Commun. 2018 May 15;9(1):1908. (PMID: 29765039)
Mol Med Rep. 2016 Nov;14(5):4445-4453. (PMID: 27666726)
Int J Mol Sci. 2018 Dec 13;19(12):. (PMID: 30551640)
Cancers (Basel). 2019 Jun 28;11(7):. (PMID: 31261718)
Oncotarget. 2017 May 16;8(20):33621-33630. (PMID: 28422725)
Sci Rep. 2018 Jan 16;8(1):829. (PMID: 29339789)
Cancers (Basel). 2018 Aug 16;10(8):. (PMID: 30115848)
Cells. 2019 Aug 18;8(8):. (PMID: 31426611)
Cancer Discov. 2016 Feb;6(2):188-201. (PMID: 26586766)
Cancer Lett. 2017 Feb 1;386:168-178. (PMID: 27887917)
Oncol Rep. 2019 Feb;41(2):1131-1139. (PMID: 30535472)
Mol Cancer Res. 2015 Apr;13(4):651-8. (PMID: 25573951)
Biomed Pharmacother. 2017 Feb;86:450-456. (PMID: 28012924)
Cell Cycle. 2019 Jul;18(14):1660-1669. (PMID: 31204563)
J Cell Sci. 2008 May 15;121(Pt 10):1649-60. (PMID: 18430781)
Clin Cancer Res. 2011 Jul 1;17(13):4600-9. (PMID: 21610145)
Autophagy. 2017 Feb;13(2):264-284. (PMID: 27929731)
Breast Cancer Res. 2017 Dec 19;19(1):133. (PMID: 29258605)
Oncotarget. 2016 Dec 27;7(52):87091-87099. (PMID: 27893429)
Autophagy. 2018;14(2):207-215. (PMID: 28933638)
Cell Death Dis. 2018 Sep 17;9(10):936. (PMID: 30224667)
Exp Cell Res. 2019 Feb 1;375(1):73-81. (PMID: 30586549)
Neuro Oncol. 2017 Jan;19(1):55-65. (PMID: 27471108)
Cancer Lett. 2018 Jul 28;427:74-84. (PMID: 29702194)
Nucleic Acids Res. 2018 Feb 16;46(3):1266-1279. (PMID: 29244158)
Int J Mol Sci. 2019 Jul 11;20(14):. (PMID: 31336784)
Cancer Lett. 2017 Nov 1;408:102-111. (PMID: 28844709)
Cell Rep. 2012 Sep 27;2(3):591-602. (PMID: 22921398)
J Biol Chem. 2016 Nov 25;291(48):25179-25191. (PMID: 27738106)
Cancers (Basel). 2017 Sep 19;9(9):. (PMID: 28925933)
Nat Rev Cancer. 2017 Sep;17(9):528-542. (PMID: 28751651)
Oncol Rep. 2019 Mar;41(3):1759-1768. (PMID: 30569180)
Jpn J Clin Oncol. 2015 May;45(5):474-82. (PMID: 25921099)
Cells. 2016 Apr 06;5(2):. (PMID: 27058560)
Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9066-E9075. (PMID: 29073103)
Nature. 2013 Dec 12;504(7479):296-300. (PMID: 24305049)
Cancers (Basel). 2019 Jan 24;11(2):. (PMID: 30682793)
Nature. 2015 Nov 26;527(7579):472-6. (PMID: 26560033)
Cells. 2018 Nov 10;7(11):. (PMID: 30423843)
BMB Rep. 2018 Sep;51(9):456-461. (PMID: 30037365)
Cancer Res. 2017 May 1;77(9):2534-2547. (PMID: 28209613)
PLoS One. 2011;6(6):e20965. (PMID: 21677772)
Autophagy. 2014 Mar;10(3):442-52. (PMID: 24418846)
Cancers (Basel). 2019 Jan 29;11(2):. (PMID: 30699970)
Autophagy. 2015;11(2):225-38. (PMID: 25607466)
Cancers (Basel). 2019 Jan 17;11(1):. (PMID: 30658414)
BMC Cancer. 2019 Jun 18;19(1):602. (PMID: 31215481)
Acta Pharm Sin B. 2019 May;9(3):639-647. (PMID: 31193825)
Biomed Res Int. 2018 Jan 15;2018:9651320. (PMID: 29568775)
Sci Rep. 2017 Jun 21;7(1):4002. (PMID: 28638102)
Cell Death Dis. 2018 Feb 22;9(3):312. (PMID: 29472524)
Oncotarget. 2016 Jan 5;7(1):538-49. (PMID: 26623719)
J Exp Clin Cancer Res. 2018 May 9;37(1):100. (PMID: 29743122)
Int J Biochem Cell Biol. 2018 Sep;102:59-70. (PMID: 29953965)
Oncotarget. 2016 Nov 15;7(46):75118-75129. (PMID: 27738333)
Cancers (Basel). 2014 Apr 10;6(2):860-78. (PMID: 24727247)
Chem Biol Interact. 2018 Jan 25;280:45-50. (PMID: 29191453)
Exp Biol Med (Maywood). 2013 Sep;238(9):1024-32. (PMID: 23925649)
Autophagy. 2017 Apr 3;13(4):761-762. (PMID: 28118076)
J Neurooncol. 2018 Jul;138(3):499-508. (PMID: 29876787)
J Cell Biol. 2010 Sep 6;190(5):881-92. (PMID: 20819940)
Genome Biol. 2019 Jan 14;20(1):12. (PMID: 30642385)
Oncotarget. 2015 Oct 20;6(32):32586-601. (PMID: 26452129)
Oncogenesis. 2015 Nov 30;4:e177. (PMID: 26619402)
Oncotarget. 2015 Feb 20;6(5):3147-64. (PMID: 25605243)
Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6139-44. (PMID: 21444814)
J Cell Sci. 2009 Jul 15;122(Pt 14):2554-66. (PMID: 19549685)
World J Gastroenterol. 2017 Apr 7;23(13):2337-2345. (PMID: 28428713)
Br J Cancer. 2012 Oct 9;107(8):1361-73. (PMID: 22929890)
Cancer Sci. 2018 May;109(5):1404-1413. (PMID: 29575368)
J Pathol. 2016 Aug;239(4):459-72. (PMID: 27171498)
Cell Prolif. 2017 Jun;50(3):. (PMID: 28217977)
Drug Resist Updat. 2015 Jan;18:1-17. (PMID: 25554624)
Cancer Res. 2017 Jan 1;77(1):198-206. (PMID: 27793847)
Oncotarget. 2017 Jul 25;8(30):49807-49823. (PMID: 28591704)
Int J Mol Med. 2016 Apr;37(4):1030-8. (PMID: 26935807)
Cell Metab. 2018 Jan 9;27(1):136-150.e5. (PMID: 29249690)
Autophagy. 2015;11(2):355-72. (PMID: 25701353)
RNA. 2015 Jun;21(6):1055-65. (PMID: 25852169)
Cancers (Basel). 2014 Sep 05;6(3):1769-92. (PMID: 25198391)
Oncogene. 2016 Sep 8;35(36):4828. (PMID: 27477697)
Cancer Lett. 2019 May 28;450:1-13. (PMID: 30776481)
Clin Cancer Res. 2016 Jul 15;22(14):3537-49. (PMID: 26858310)
EMBO J. 2011 Sep 13;30(22):4628-41. (PMID: 21915098)
Int J Oncol. 2019 Jan;54(1):326-338. (PMID: 30365045)
Cell Death Dis. 2017 Jan 12;8(1):e2540. (PMID: 28079894)
Cancers (Basel). 2016 Dec 09;8(12):. (PMID: 27941677)
J Exp Clin Cancer Res. 2017 Nov 29;36(1):171. (PMID: 29187221)
Cell Physiol Biochem. 2015;37(6):2366-74. (PMID: 26646296)
Genes Dev. 2015 Mar 1;29(5):489-94. (PMID: 25737278)
Int J Nanomedicine. 2018 Mar 01;13:1241-1256. (PMID: 29535520)
Oncogene. 2011 Dec 1;30(48):4814-23. (PMID: 21625209)
Theranostics. 2017 Oct 17;7(19):4777-4790. (PMID: 29187903)
Cancer Lett. 2018 Jun 1;423:113-126. (PMID: 29196128)
Sci Signal. 2019 Feb 26;12(570):. (PMID: 30808819)
Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63. (PMID: 17911267)
Cancer Res. 2016 Aug 1;76(15):4504-15. (PMID: 27312529)
Cell Death Dis. 2019 Sep 11;10(9):666. (PMID: 31511498)
Int J Mol Med. 2019 Jan;43(1):517-524. (PMID: 30365062)
J Exp Clin Cancer Res. 2017 Mar 9;36(1):41. (PMID: 28279221)
Oncol Lett. 2019 Oct;18(4):3837-3844. (PMID: 31579087)
Mol Cells. 2018 May 31;41(5):390-400. (PMID: 29754469)
Int J Cancer. 2019 Jul 15;145(2):435-449. (PMID: 30650179)
Am J Transl Res. 2017 Aug 15;9(8):3599-3610. (PMID: 28861151)
Grant Information:: 2017R1D1A3B03035662 International Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education; 2019R1A6A1A11036849 International Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education; 2019R1A2C1089710 International National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT); 2019R1A5A2027588 International National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)
Contributed Indexing:: Keywords: cancer; chemosensitization; combination therapy; microRNA; therapeutic resistance
Substance Nomenclature:: 0 (Antineoplastic Agents)
0 (MicroRNAs)
Entry Date(s):: Date Created: 20191222 Date Completed: 20200826 Latest Revision: 20200826
Update Code:: 20240105
PubMed Central ID:: PMC7016872
DOI:: 10.3390/cells9010029
PMID:: 31861937
: Czasopismo naukowe

Full Text Finder

The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission. To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable. MicroRNA (miRNAs) are associated with cancer therapeutic resistance. The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies. The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes associated with the signaling pathways controlling therapeutic resistance. In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer. We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy. We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.
Competing Interests: The authors declare no conflict of interest.

Informacja